Takeda Pharmaceutical Company Limited (TAK)

American Depository Receipts

Sell: $13.80|Buy: $14.20|Change: 0.02 (0.14%)

Not yet a customer?

Low cost dealing from £1.50

Choose from our range of SIPP, ISA and Dealing accounts

Open

$13.86

Previous close

$13.86

Trade high

$13.95

Volume

3,105,669

Year high

$15.69

Year low

$12.80

Dividend yield

4.8%

Market capitalisation

$43.84 bn

P/E ratio

49.41

ISIN

US8740602052

This share can be held in a Dealing account Stocks and shares ISA Lifetime ISA JISA SIPP

Share price

Dividends

	Previous	Latest
Record date	30/09/2024	31/03/2025
Ex-dividend date	30/09/2024	31/03/2025
Payment date	12/12/2024	07/07/2025
Amount	$0.32608	$0.33901

Performance 16/10/2025

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann

	Total return (%)
Takeda Pharmaceutical Company Limited	+ 0.14
More...

Company profile

Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.

Sector

Healthcare

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.